
Food and Drug Administration nominee Dr. Heidi Overton committed to a timeline for a delayed mifepristone safety study, Sen. Josh Hawley's office says.
Friday, 20 November 2026
Connect your wallet to join the discussion.
No comments yet. Be the first to share your take.